335
Views
7
CrossRef citations to date
0
Altmetric
Letter to the Editor

Successful Tocilizumab Treatment for Scleritis

, &
Pages 285-287 | Received 19 Feb 2019, Accepted 08 May 2019, Published online: 14 Aug 2019

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Melis Kabaalioğlu Güner, Ankur Mehra & Wendy M. Smith. (2021) Novel strategies for the diagnosis and treatment of scleritis. Expert Review of Ophthalmology 16:6, pages 431-448.
Read now
Emmett T. Cunningham, Alfredo Adán, Quan Dong Nguyen & Manfred Zierhut. (2021) Tocilizumab for the Treatment of Ocular Inflammatory Disease. Ocular Immunology and Inflammation 29:1, pages 2-5.
Read now

Articles from other publishers (5)

Ahmad Abdel-Aty, Akash Gupta, Lucian Del Priore & Ninani Kombo. (2022) Management of noninfectious scleritis. Therapeutic Advances in Ophthalmology 14, pages 251584142110708.
Crossref
Jurgen Sota, Matteo-Maria Girolamo, Bruno Frediani, Gian Marco Tosi, Luca Cantarini & Claudia Fabiani. (2021) Biologic Therapies and Small Molecules for the Management of Non-Infectious Scleritis: A Narrative Review. Ophthalmology and Therapy 10:4, pages 777-813.
Crossref
Florian Cohen, Eric Ernest Gabison, Sophie Stéphan, Rakiba Belkhir, Gaetane Nocturne, Anne-Laurence Best, Oscar Haigh, Emmanuel Barreau, Marc Labetoulle, Raphaele Seror & Antoine Rousseau. (2021) Peripheral ulcerative keratitis in rheumatoid arthritis patients taking tocilizumab: paradoxical manifestation or insufficient efficacy?. Rheumatology 60:11, pages 5413-5418.
Crossref
Parthopratim Dutta Majumder, Rupesh Agrawal, Peter McCluskey & Jyotirmay Biswas. (2021) Current Approach for the Diagnosis and Management of Noninfective Scleritis. Asia-Pacific Journal of Ophthalmology 10:2, pages 212-223.
Crossref
. (2020) Prednisone. Reactions Weekly 1797:1, pages 201-201.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.